Lantheus Medical Imaging to Present at Imperial Capital Global Opportunities Conference on September 18, 2014
N. Billerica, Mass., September 10, 2014 – Lantheus Medical Imaging, Inc., a global leader in developing, manufacturing, selling and distributing innovative diagnostic imaging agents, today announced that it will be participating in the Imperial Capital Global Opportunities Conference on Thursday, September 18, 2014 in New York City. Jeff Bailey, President and Chief Executive Officer, will present at 9:30 a.m., Eastern Time.
To access a live webcast of the presentation, please visit the Company’s website at www.lantheus.com. A replay of the presentation will be available on the Company’s website for 30 days following the live presentation.
About Lantheus Medical Imaging, Inc.
Lantheus Medical Imaging, Inc. is a global leader in developing, manufacturing, selling and distributing innovative diagnostic imaging agents. The Company provides a broad portfolio of products, which are primarily used for the diagnosis of cardiovascular diseases. Lantheus’ key products include the echocardiography contrast agent DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; TechneLite® (Technetium Tc99m Generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; and Xenon (Xenon Xe 133 Gas), an inhaled radiopharmaceutical imaging agent used to evaluate pulmonary function and for imaging the lungs.
Lantheus has more than 500 employees worldwide with headquarters in North Billerica, Massachusetts, and offices in Puerto Rico, Canada and Australia. For more information, visit www.lantheus.com.